About Us

Shenzhen Lingrui Biotechnology Co., Ltd., established in 2017 and headquartered in Shenzhen,  has a factory in Suzhou covering over 12,000 square meters/cGMP factory space. It is the only company in China with proprietary intellectual property rights for self-administration injection devices, having undergone FTO infringement analysis and obtained 110 patents, with 33 additional patents pending.

Lingrui Biotech integrates research, development, production, and sales, boasting an 83-member R&D team composed of multidisciplinary scientists and engineers from fields such as biology, chemistry, medicine, mechanics, materials, electronics, automation, and computer science.

Our product portfolio includes single-use auto-injectors, multi-dose adjustable injectors, PFS needlestick protection devices, electronic pens, and nasal spray devices. The company also provides commercial semi-automatic and fully automatic assembly lines for outsourced material assembly, catering to customized client needs.

Lingrui Biotech focuses on the diverse needs of the self-administration industry, offering solutions for autoimmune self-administration, emergency management, and chronic disease self-administration across various scenarios. With over 40 clients both China domestically and internationally, the company aims to expand its injector production capacity to 100 million units between 2024 and 2025, striving to become a global leader in “self-administration device” comprehensive solutions.